Helios Corp. ~ Diabetinol

BLOOMINGTON, Ind.Helios Corp., in cooperation in Summit Resource Group, announced Diabetinol, a patented ingredient for the treatment of glucose intolerance. With the substantial cost of diabetes drugs in the United States, Diabetinol provides a natural choice for those who suffer from diabetes with ingredients derived from citrus components.

Active drugs are constantly under review with the FDA for potential side effects. Therefore, any natural ingredients for the glucose intolerance category are most likely combined with a pharma active. Helios phase one clinical study showed the performance of Diabetinol as a stand alone. The company, Helios, finished a phase two clinical evaluation which demonstrated how Diabetinol can play a significant role in the successful management of glucose intolerance. Phase two clinically demonstrated compatibility with active drugs and also demonstrated benefits toward performance in the active group.